Stephens Inc. AR Decreases Stock Holdings in Charles River Laboratories International, Inc. (NYSE:CRL)

Stephens Inc. AR lowered its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRLGet Rating) by 3.3% during the first quarter, Holdings Channel reports. The institutional investor owned 1,739 shares of the medical research company’s stock after selling 60 shares during the period. Stephens Inc. AR’s holdings in Charles River Laboratories International were worth $494,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. State Street Corp boosted its holdings in Charles River Laboratories International by 3.7% during the fourth quarter. State Street Corp now owns 2,030,795 shares of the medical research company’s stock worth $765,163,000 after buying an additional 73,315 shares in the last quarter. Kayne Anderson Rudnick Investment Management LLC raised its position in Charles River Laboratories International by 4.8% during the fourth quarter. Kayne Anderson Rudnick Investment Management LLC now owns 1,552,655 shares of the medical research company’s stock worth $585,009,000 after acquiring an additional 70,850 shares during the last quarter. William Blair Investment Management LLC raised its position in Charles River Laboratories International by 14.2% during the fourth quarter. William Blair Investment Management LLC now owns 1,076,250 shares of the medical research company’s stock worth $405,509,000 after acquiring an additional 133,654 shares during the last quarter. Geode Capital Management LLC raised its position in Charles River Laboratories International by 1.5% during the fourth quarter. Geode Capital Management LLC now owns 924,738 shares of the medical research company’s stock worth $347,506,000 after acquiring an additional 13,586 shares during the last quarter. Finally, King Luther Capital Management Corp raised its position in Charles River Laboratories International by 1.7% during the fourth quarter. King Luther Capital Management Corp now owns 555,100 shares of the medical research company’s stock worth $209,151,000 after acquiring an additional 9,159 shares during the last quarter. Hedge funds and other institutional investors own 93.06% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have issued reports on the stock. Guggenheim assumed coverage on shares of Charles River Laboratories International in a research report on Monday, May 23rd. They set a “neutral” rating for the company. They noted that the move was a valuation call. Deutsche Bank Aktiengesellschaft cut their target price on shares of Charles River Laboratories International from $350.00 to $290.00 and set a “buy” rating for the company in a research report on Thursday, July 14th. Wells Fargo & Company cut their price objective on shares of Charles River Laboratories International from $390.00 to $325.00 and set an “overweight” rating for the company in a research report on Monday, April 25th. Jefferies Financial Group lowered shares of Charles River Laboratories International from a “buy” rating to a “hold” rating and cut their price objective for the company from $370.00 to $280.00 in a research report on Monday, April 25th. Finally, Stephens set a $315.00 price objective on shares of Charles River Laboratories International in a research report on Monday, June 20th. Four research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $376.00.

Charles River Laboratories International Stock Performance

Shares of CRL stock opened at $221.38 on Thursday. Charles River Laboratories International, Inc. has a one year low of $203.37 and a one year high of $460.21. The company has a debt-to-equity ratio of 1.02, a quick ratio of 1.12 and a current ratio of 1.34. The company has a 50 day moving average price of $226.56 and a 200 day moving average price of $263.64. The firm has a market capitalization of $11.25 billion, a price-to-earnings ratio of 26.96, a price-to-earnings-growth ratio of 1.55 and a beta of 1.29.

Charles River Laboratories International (NYSE:CRLGet Rating) last released its quarterly earnings data on Wednesday, August 3rd. The medical research company reported $2.77 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.74 by $0.03. Charles River Laboratories International had a net margin of 11.64% and a return on equity of 21.90%. The company had revenue of $973.13 million during the quarter, compared to the consensus estimate of $995.12 million. During the same period in the previous year, the firm earned $2.61 earnings per share. Charles River Laboratories International’s revenue for the quarter was up 6.4% on a year-over-year basis. Sell-side analysts anticipate that Charles River Laboratories International, Inc. will post 11.5 EPS for the current year.

Insiders Place Their Bets

In other Charles River Laboratories International news, Director George Massaro sold 178 shares of the business’s stock in a transaction that occurred on Monday, May 9th. The shares were sold at an average price of $230.96, for a total transaction of $41,110.88. Following the completion of the sale, the director now directly owns 4,677 shares in the company, valued at $1,080,199.92. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 1.10% of the stock is owned by insiders.

About Charles River Laboratories International

(Get Rating)

Charles River Laboratories International, Inc, a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).

Read More

Want to see what other hedge funds are holding CRL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Charles River Laboratories International, Inc. (NYSE:CRLGet Rating).

Institutional Ownership by Quarter for Charles River Laboratories International (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International and related companies with MarketBeat.com's FREE daily email newsletter.